Valion Bio (VBIO) Non Operating Income (2021 - 2025)

Valion Bio (VBIO) posted quarterly Non Operating Income of -$113000.0 for Q3 2025, down 3866.67% quarter-over-quarter from $3000.0 in Q2 2025.

Valion Bio (VBIO) Non Operating Income (2021 - 2025) Analysis & Trends

Valion Bio's Non Operating Income history runs 4 years deep, the most recent figure standing at -$113000.0 for Q3 2025.

In Q3 2025, Non Operating Income changed N/A year-over-year to -$113000.0; the TTM figure through Sep 2025 stood at -$100000.0 (down 72.41% YoY), while the FY2024 annual figure was $6000.0, up 500.0% from the prior year.
Non Operating Income for Q3 2025 stood at -$113000.0, down from $3000.0 in the prior quarter.
The five-year high for Non Operating Income was $6000.0 in Q4 2024, with the low at -$1.4 million in Q4 2021.
The 4-year median for Non Operating Income is -$39000.0 (2021), against an average of -$274363.6.
The sharpest annual moves came in 2022 and 2025: Non Operating Income surged 100.14% in 2022, then soared 105.0% in 2025.
Valion Bio's Non Operating Income stood at -$1.4 million in 2021, then soared by 100.14% to $2000.0 in 2022, then surged by 200.0% to $6000.0 in 2024, then sank by 1983.33% to -$113000.0 in 2025.
Business Quant data shows VBIO's Non Operating Income at -$113000.0 in Q3 2025, $3000.0 in Q2 2025, and $4000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Op. Inc. (Qtr)
1	Vertex Pharmaceuticals	140.52 Bn	132.67 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.54 Bn	78.55 Bn	3.93 Bn	234.30 Mn
3	Argenx Se	65.31 Bn	60.13 Bn	1.37 Bn	-
4	Moderna	61.77 Bn	56.64 Bn	52.00 Mn	-
5	BeOne Medicines	42.26 Bn	37.16 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.19 Bn	27.88 Bn	992.69 Mn	-53.64 Mn
7	BioNTech SE	28.71 Bn	10.31 Bn	668.28 Mn	-
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
9	Royalty Pharma	27.35 Bn	26.52 Bn	-	-51.63 Mn
10	Valion Bio	441,427.63	-1.76 Mn	-45,000.00	-

Download Data